Materiały źródłowe

• #1 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  Most conditions that cause thrombocytosis, including essential thrombocythemia, arent preventable. […] Your provider may recommend a few treatment options if you have essential thrombocythemia and are experiencing symptoms: Taking a daily low-dose aspirin: You can take a daily aspirin to prevent blood clots. […] Theres no cure for essential thrombocytosis, but your healthcare provider can help you manage the condition to reduce your risk of clots.

• #1 Screening and Prevention of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/screening-and-prevention

  You can’t prevent primary thrombocythemia. However, you can take steps to reduce your risk for complications. For example, you can control many of the risk factors for blood clots, such as high blood cholesterol, high blood pressure, diabetes, and smoking. […] To reduce your risk, quit smoking, adopt healthy lifestyle habits, and work with your doctor to manage your risk factors. […] It’s not always possible to prevent conditions that lead to secondary thrombocytosis. But, if you have routine medical care, your doctor may detect these conditions before you develop a high platelet count.

• #1 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Treatment for essential thrombocytosis (primary thrombocythemia) is aimed at preventing complications and alleviating symptoms; it does not necessarily prolong survival or slow disease progression. It should be individualized on the basis of risk factors for thrombosis or bleeding. Risk factors include the following: […] Lifestyle modifications should be recommended for all patients with reversible risk factors. These include diet and exercise to promote weight loss for obese patients and smoking cessation for smokers. […] The IPSET-thrombosis risk calculator may be used for risk stratification. It stratifies patients into very-low-risk, low-risk, intermediate-risk, and high-risk categories. […] Observation may be appropriate for very-low-risk patients (ie, those lacking any of the above risk factors), although once-daily aspirin may be used in those with cardiovascular risk factors or symptoms.

• #1 Essential thrombocythemia: Symptoms, treatment, and more

  https://www.medicalnewstoday.com/articles/essential-thrombocythemia

  Currently, there is no way to prevent ET, as it often arises from genetic mutations. However, people can reduce their risk of complications by adopting a heart-healthy lifestyle, including: […] Early detection through routine blood tests is also critical for those with a family history of MPNs or other risk factors.

• #1 Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10230439/

  Prevention of recurrent thrombosis in ET patients must follow the general guidelines for secondary prevention in the general population, including antiplatelet agents and anticoagulant drugs, depending on the clinical setting. Primary prevention of thrombosis is based on the prophylactic use of low-dose aspirin (81-100 mg daily) and cytoreduction. Aspirin is recommended for all risk categories, with the exception of patients at very low risk, who should only be given aspirin for treatment of vasomotor/microvascular disturbances; cytoreduction with hydroxyurea or, alternatively, with peginterferon 2a or anagrelide is usually restricted to high-risk patients. Cytoreductive treatment should, however, also be considered in other risk categories, depending on the presence of additional conditions, such as von Willebrand disease, extreme thrombocytosis and/or leukocytosis, splenomegaly, vasomotor/microvascular disturbances or other disease-related symptoms not responsive to aspirin.

• #1 Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10230439/

  The efficacy of aspirin in controlling vasomotor/microvascular disturbances is well recognized, despite the lack of controlled trials, thanks to the dramatic improvement of patients signs and symptoms in response to aspirin treatment. […] The efficacy of aspirin in primary prevention of major thrombotic events in ET has not been documented by randomized controlled trials. The potential benefit of aspirin is inferred from analogies with its use in polycythemia vera, in which low-dose aspirin has been shown to cause an approximately 60% reduction in the risk of the combined endpoint of non-fatal myocardial infarction, nonfatal stroke or death from cardiovascular causes and of venous thromboembolism, without increasing the risk of bleeding complications. […] Overall, protection from thrombosis by aspirin in ET appeared modest in a systematic review of 24 observational studies including 6,153 ET patients, which showed an estimated 26% reduction of thrombotic events from antiplatelet therapy (aspirin in 80% of patients), lower than that observed in polycythemia vera.

• #1 Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10230439/

  Low-dose aspirin is the recommended treatment for the control of vascular events in all risk categories of ET patients, with the exception of patients at very low risk, who should be given aspirin for treatment of vasomotor/microvascular disturbances only. A simple observational approach should be preferred over aspirin prophylaxis in low-risk patients with platelet counts 1,000×109/L or harboring CALR mutations. Cytoreduction should be preferred over aspirin prophylaxis for high-risk or symptomatic patients with platelet counts 1,000/109/L. […] When treated with the once daily aspirin regimen, most ET patients do not display virtually complete inhibition of platelet TxA2 production persisting for 24 hours, which is necessary for the prevention of thrombosis. This phenomenon is attributable to the increased daily platelet production, which causes the presence of a high number of immature platelets with non-acetylated COX-1 in the circulation. Several studies showed that twice daily aspirin administration overcomes this problem.

• #1 Essential Thrombocytosis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/30099

  Hydroxyurea has been shown to reduce both the number of platelets and the number of leukocytes, causing a reduction in thrombosis and myelofibrosis. […] Anagrelide, on the other hand, is a second-line therapy used to reduce platelet count. […] For pregnant ETT patients, concurrent low molecular weight heparin (LMWH) with low-dose aspirin is advocated, the latter withdrawn should bleeding occur. […] The use of Aspirin in the pediatric group raises some trepidation over the appearance of Reyes syndrome. […] Essential thrombocytosis is not curable; however, patients should be aware that to prevent complications from the disease, they have to be compliant with recommended medications. […] It is imperative to find a cure, as complications due to stroke and myocardial infarction could be deadly and cause untimely deaths in high-risk patients.

• #1 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Low-risk patients (ie, those whose only risk factor is JAK2 or MPL mutation) can be treated with daily low-dose aspirin therapy. […] Intermediate-risk patients may benefit from both aspirin and cytoreductive agents (eg hydroxyurea). […] High-risk patients benefit from both aspirin and cytoreductive agents (see next section for further discussion on these agents). […] Plateletpheresis may be indicated as an emergency intervention, to achieve a rapid decrease in platelet counts in the setting of acute thrombosis and/or marked thrombocytosis.

• #1 Treatment of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/treatment-thrombocythemia

  Taking aspirin may help people who are at risk for blood clots (aspirin thins the blood). However, talk with your doctor about using aspirin because it can cause bleeding. […] Currently, hydroxyurea plus aspirin is the standard treatment for people who have primary thrombocythemia and are at high risk for blood clots. […] Doctors may prescribe this medicine to pregnant women who have primary thrombocythemia because it’s safer for a fetus than hydroxyurea and anagrelide. […] Plateletpheresis (PLATE-let-fe-REH-sis) is a procedure used to rapidly lower your platelet count. This procedure is used only for emergencies. For example, if you’re having a stroke due to primary thrombocythemia, you may need plateletpheresis.

• #1 Patients with essential thrombocytosis during pregnancy: Challenges and therapeutic dilemmas

  https://www.oatext.com/patients-with-essential-thrombocytosis-during-pregnancy-challenges-and-therapeutic-dilemmas.php

  Treatment of patients with essential thrombocytosis during pregnancy is challenging and young women are reported to be at increased risk of first trimester abortions and other pregnancy complications. […] The addition of low dose aspirin seems to be beneficial in most cases improving pregnancy outcome whereas interferon-a is the cytoreductive drug of choice when platelet control is needed during pregnancy. […] Current recommendations suggest that ASA and cytoreductive therapy should be offered for high-risk pregnancies, especially when there is thrombotic history. […] Special attention was given in the beneficial role of ASA when was given in patients with known ET, which was continued throughout pregnancy. ASA appeared to increase the percentage of live births with less pregnancy complications.

• #1 Patients with essential thrombocytosis during pregnancy: Challenges and therapeutic dilemmas

  https://www.oatext.com/patients-with-essential-thrombocytosis-during-pregnancy-challenges-and-therapeutic-dilemmas.php

  Treatment recommendations of patients with criteria of cytoreductive treatment (like platelet count 1500000/l or thrombosis) while conceiving, suggest IFNa to be the safest option. […] Treatment with ASA might positively influence the outcome of pregnancy due to reduced probability of placental infarctions. […] The addition of LMWH is not recommended even if there are published reports of successful pregnancies after the combination of both drugs in women with history of severe pregnancy complications including fetal death. […] However, LMWH is reasonable to be considered in women with history of thromboembolic events in the past and high-risk pregnancies for thrombotic potential. […] Thus, prospective studies are needed in order to reconsider the risk of pregnancies, to find the patients who could benefit of more intensive anticoagulation or cytoreductive treatment focusing on the safety of drugs for both the pregnant patient and the fetus.

• #1 https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia

  https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia

  ET does not generally shorten life expectancy. However, medical supervision is important to prevent or treat thrombosis, a serious complication that can affect vital organs such as the brain or the heart. […] A patient with secondary, or reactive, thrombocytosis should have a return to normal platelet count in the blood once the primary problem is treated successfully.

• #1

  https://journals.lww.com/ijab/fulltext/2015/05030/postoperative_thrombocytosis__an_unusual_case.20.aspx

  The risk of thrombotic complications with reactive thrombocytosis is felt to be low, as 1.6% of patients with reactive thrombocytosis had thrombotic complications in one large case series. […] Even in cases of extreme reactive thrombocytosis, the risk of thrombotic complication is relatively low (4-6%).

• #1

  https://journals.lww.com/ijab/fulltext/2015/05030/postoperative_thrombocytosis__an_unusual_case.20.aspx

  Thrombocytosis is often an incidental finding seen in 35-50% of cases and the cause determination creates a diagnostic challenge. […] The appearance of thrombocytosis after surgery needs to be diagnosed to establish the type of thrombocytosis (clonal or reactive), as treatment and prognosis are quite different between them. […] We suggested monitoring platelet count throughout the postoperative period by serial analytical, with introduction of thromboembolic prophylaxis and control of bleeding in the face of the probability of some degree of platelet dysfunction. […] Postoperative antithrombotic prophylaxis and bleeding monitoring were maintained until the patient was discharged after 2 weeks of admission, to follow up with outpatient treatment. […] Prophylactic treatment with platelet inhibitors in these situations is controversial, although some authors do consider management of low-dose acetylsalicylic acid appropriate.

• #1 Secondary severe thrombocytosis in a patient who underwent splenectomy due to hereditary spherocytosis and its treatment using hydroxyurea

  https://www.panafrican-med-journal.com/content/article/32/175/full/

  Thrombocytosis is a frequently seen condition during childhood. Treatment is not recommended in patients who are asymptomatic and with a platelet count below 1,500,000/mm3, however, treatment is required in cases who are symptomatic and with a platelet count above 1,500,000/mm3 in conditions such as primary thrombocytosis. […] The most important point in the follow-up and treatment of thrombocytosis is to determine the etiology. […] The most commonly used medication in treatment is acetylsalicylic acid. […] Hydroxyurea treatment was planned to be initiated. […] It is recommended to start the treatment at a dose of 15mg/kg/day and adjust the dose based on follow-up. […] We emphasize that in patients with secondary thrombocytosis, low-dose hydroxyurea treatment can be used safely when the platelet count is above 1,500,000/mm3 for a long period of time and the risk of thrombosis is high, and platelet count can be reduced to safe levels.

• #1

  https://haematologica.org/article/view/4771

  Aspirin is indicated for patients at moderate risk and is strongly recommended for subjects at higher risk levels. […] Hydroxyurea is indicated in high risk subjects and absolutely recommended in very high risk subjects of any age. […] The retrospective analysis by De Stefano et al. suggests that the thrombotic risk is highest in the 2 years after the first thrombotic event and slowly declines thereafter. […] More aggressive anti-thrombotic therapy, based on the combination of aspirin with clopidogrel in patients with previous myocardial infarction, or with dypyridamole in patients with previous transient ischemic attacks or stroke, might be most beneficial in the 3 to 4 years following the thrombotic event.

• #1

  https://link.springer.com/article/10.1007/s12471-023-01757-4

  An alternative way to prevent recurrent arterial events might be the use of more aggressive, e.g. double antiplatelet, therapy in the first 3-4 years following an arterial thrombotic event. […] Importantly, antiplatelet therapy plus anticoagulants should be used with caution, since their co-use was shown to result in an almost three times higher incidence of major bleeding as compared to either antiplatelet drugs or anticoagulants alone.

• #1 Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist | mijn-bsl

  https://mijn.bsl.nl/essential-thrombocytosis-diagnosis-differential-diagnosis-compli/24011868

  Treatment of ET should be individualised, bearing in mind all possible complications of ET ranging from thrombotic and haemorrhagic events, the presence of risk factors, and the risk of progression to myelofibrosis or myeloid leukaemia. […] With regard to the prevention of thrombotic complications in ET, the advocated approach, based on risk stratification by a history of (arterial or venous) thrombosis, age 60 years, the presence of a JAK2 mutation and cardiovascular risk factors, is presented in Tab. 3. […] An alternative way to prevent recurrent arterial events might be the use of more aggressive, e.g. double antiplatelet, therapy in the first 34 years following an arterial thrombotic event. […] Importantly, antiplatelet therapy plus anticoagulants should be used with caution, since their co-use was shown to result in an almost three times higher incidence of major bleeding as compared to either antiplatelet drugs or anticoagulants alone.

• #1 https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  Prevention of blood clots (thrombosis) and bleeding (hemorrhaging) is the main objective of treating patients with ET. […] For patients with low-risk disease and no symptoms, the risk of complications may be low the doctor may prescribe low-dose aspirin or no therapy at all. […] On the other hand, for patients with high-risk disease, doctors may prescribe low-dose aspirin and other medications to reduce high platelet counts. […] Low-dose aspirin may reduce the risk of clotting complications. Low-dose aspirin helps prevent platelets from sticking together, making it less likely for blood clots to form that can cause heart attacks or strokes. […] Low-dose aspirin may also increase bleeding risk in patients with extremely high platelet counts. For these reasons, the use of aspirin in treating ET needs to be individualized.

• #1 Essential Thrombocythemia: Definition, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/24031-essential-thrombocythemia

  Even if you have symptoms, providers can provide treatments to prevent serious complications such as stroke or heart attack. […] Healthcare providers can’t cure essential thrombocythemia, but they can prevent blood clots with treatments that reduce platelet levels and your risk of heart attack or stroke.

• #2 Essential Thrombocythemia: Definition, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/24031-essential-thrombocythemia

  Essential thrombocythemia is a rare genetic disorder that affects platelets, the blood cells that control bleeding. […] Healthcare providers treat this condition by reducing platelet levels, which reduces the risk of serious complications. […] Essential thrombocythemia is an acquired genetic condition, meaning it happens when certain genes mutate or change. […] Essential thrombocythemia is not curable but treatment may reduce the risk you’ll develop serious complications. […] Essential thrombocythemia can cause blood clots anywhere in your body, especially in your brain, hands and feet. […] Women who are pregnant or planning to become pregnant have additional risk of developing blood clots during pregnancy. […] This condition may also cause unusual or excessive bleeding. […] Essential thrombocythemia is an example of a myeloproliferative neoplasm.

• #2 Screening and Prevention of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/screening-and-prevention

  You can’t prevent primary thrombocythemia. However, you can take steps to reduce your risk for complications. For example, you can control many of the risk factors for blood clots, such as high blood cholesterol, high blood pressure, diabetes, and smoking. […] To reduce your risk, quit smoking, adopt healthy lifestyle habits, and work with your doctor to manage your risk factors. […] It’s not always possible to prevent conditions that lead to secondary thrombocytosis. But, if you have routine medical care, your doctor may detect these conditions before you develop a high platelet count.

• #2 Essential Thrombocytosis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/30099

  The goal of the treatment of essential thrombocytosis is to prevent vascular complications such as thrombotic and hemorrhagic events; this is because thrombosis and hemorrhage are the leading causes of morbidity and mortality. […] Risk stratification is used to determine whether the patient should receive treatment or not. Therefore, treatment strategy depends on whether the patient is at low or high risk for thrombosis. Generally, low-risk patients are young (under age 60) with no prior thrombosis, and high-risk patients are as older (over age 60) with a previous history of thrombosis. […] For a low-risk patient, it is recommended to treat with aspirin if there are no major contraindications for aspirin. […] For a high-risk patient, antiplatelet (low-dose aspirin) and cytoreductive therapy are the choice.

• #2

  https://haematologica.org/article/view/4771

  Identifying the most safe and effective strategy for reducing the vascular risk of subjects with polycythemia vera and essential thrombocythemia has always been challenging. […] The assignment of a patient to a certain risk level is based tentatively on a simple scoring system (Table 2). This has the advantage of considering the impact of age in a more plausible progressive manner than that based on a single threshold level. Other risk factors are a past history of thrombosis, smoking and high leukocyte count, whose role has been shown by large clinical studies. […] The scoring system includes a platelet count above 10/L as a risk factor only because there is wide consensus on considering marked thrombocytosis an indication for cytoreduction. […] The role of these factors is frequently neglected, as happens in other thrombophilic states, because of the tendency to consider thrombosis as caused by the single specific condition rather than by an interplay of multiple factors.

• #2 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Treatment for essential thrombocytosis (primary thrombocythemia) is aimed at preventing complications and alleviating symptoms; it does not necessarily prolong survival or slow disease progression. It should be individualized on the basis of risk factors for thrombosis or bleeding. Risk factors include the following: […] Lifestyle modifications should be recommended for all patients with reversible risk factors. These include diet and exercise to promote weight loss for obese patients and smoking cessation for smokers. […] The IPSET-thrombosis risk calculator may be used for risk stratification. It stratifies patients into very-low-risk, low-risk, intermediate-risk, and high-risk categories. […] Observation may be appropriate for very-low-risk patients (ie, those lacking any of the above risk factors), although once-daily aspirin may be used in those with cardiovascular risk factors or symptoms.

• #2

  https://haematologica.org/article/view/haematol.2022.281388

  Prevention of recurrent thrombosis in ET patients must follow the general guidelines for secondary prevention in the general population, including antiplatelet agents and anticoagulant drugs, depending on the clinical setting. Primary prevention of thrombosis is based on the prophylactic use of low-dose aspirin (81-100 mg daily) and cytoreduction. Aspirin is recommended for all risk categories, with the exception of patients at very low risk, who should only be given aspirin for treatment of vasomotor/microvascular disturbances; cytoreduction with hydroxyurea or, alternatively, with peginterferon 2a or anagrelide is usually restricted to high-risk patients. […] The efficacy of aspirin in controlling vasomotor/microvascular disturbances is well recognized, despite the lack of controlled trials, thanks to the dramatic improvement of patients signs and symptoms in response to aspirin treatment.

• #2 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Low-risk patients (ie, those whose only risk factor is JAK2 or MPL mutation) can be treated with daily low-dose aspirin therapy. […] Intermediate-risk patients may benefit from both aspirin and cytoreductive agents (eg hydroxyurea). […] High-risk patients benefit from both aspirin and cytoreductive agents (see next section for further discussion on these agents). […] Plateletpheresis may be indicated as an emergency intervention, to achieve a rapid decrease in platelet counts in the setting of acute thrombosis and/or marked thrombocytosis.

• #2 Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10230439/

  Low-dose aspirin is the recommended treatment for the control of vascular events in all risk categories of ET patients, with the exception of patients at very low risk, who should be given aspirin for treatment of vasomotor/microvascular disturbances only. A simple observational approach should be preferred over aspirin prophylaxis in low-risk patients with platelet counts 1,000×109/L or harboring CALR mutations. Cytoreduction should be preferred over aspirin prophylaxis for high-risk or symptomatic patients with platelet counts 1,000/109/L. […] When treated with the once daily aspirin regimen, most ET patients do not display virtually complete inhibition of platelet TxA2 production persisting for 24 hours, which is necessary for the prevention of thrombosis. This phenomenon is attributable to the increased daily platelet production, which causes the presence of a high number of immature platelets with non-acetylated COX-1 in the circulation. Several studies showed that twice daily aspirin administration overcomes this problem.

• #2

  https://haematologica.org/article/view/haematol.2022.281388

  The efficacy of aspirin in primary prevention of major thrombotic events in ET has not been documented by randomized controlled trials. […] A recent consensus of experts on the management of CALR-mutated ET recommends a pure observational approach over aspirin prophylaxis in asymptomatic low-risk ET patients without cardiovascular risk factors, while cytoreduction should be preferred over aspirin for low-risk symptomatic patients with a platelet count of 1,000-1,500×109/L. […] Overall, protection from thrombosis by aspirin in ET appeared modest in a systematic review of 24 observational studies including 6,153 ET patients, which showed an estimated 26% reduction of thrombotic events from antiplatelet therapy (aspirin in 80% of patients), lower than that observed in polycythemia vera. […] Low-dose aspirin is the recommended treatment for the control of vascular events in all risk categories of ET patients, with the exception of patients at very low risk, who should be given aspirin for treatment of vasomotor/microvascular disturbances only.

• #2

  https://haematologica.org/article/view/haematol.2022.281388

  Cytoreduction should be preferred over aspirin prophylaxis for high-risk or symptomatic patients with platelet counts 1,000/109/L. […] Several studies showed that twice daily aspirin administration overcomes this problem. […] The results of these studies are certainly very important and, although additional long-term safety data may be necessary to evaluate the incidence of dose-related gastrointestinal side effects, total serum TxB2 levels could already change our clinical practice.

• #2 Tests and treatment for essential thrombocythaemia (ET) | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/essential-thrombocythaemia/treatment

  Treatment for ET aims to reduce the number of platelets and lower the risk of blood clots. This helps to control your symptoms and to prevent any more serious problems. […] You usually have low dose aspirin if you are very low risk but have symptoms. […] If you have a low or intermediate risk of developing clots, you have low dose aspirin. […] Treatments for people with a high risk of developing blood clots include: low dose aspirin, hydroxycarbamide, anagrelide, busulfan, peginterferon alfa 2a. […] You take aspirin as a tablet. This can help to lower the number of platelets in the blood. This is also known as an anti platelet therapy. […] Hydroxycarbamide is a type of chemotherapy. This treatment uses cell killing (cytotoxic) drugs to destroy the extra platelets. […] Anagrelide is a medicine that is used to reduce the number of platelets.

• #2 Tests and treatment for essential thrombocythaemia (ET) | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/essential-thrombocythaemia/treatment

  Peginterferon alfa 2a is a type of immunotherapy. It stimulates cells of the immune system to attack the cancer. It can also help to control the number of platelets. […] There is a risk of complications, including blood clots, during pregnancy if you have ET. […] If you are having surgery for any reason, let your surgeon know you have ET and any treatment you may be taking.

• #2 An Update on Current and Emergent Therapies for Essential Thrombocytosis

  https://www.targetedonc.com/view/an-update-on-current-and-emergent-therapies-for-essential-thrombocytosis

  In cases where initial treatment approaches do not yield satisfactory results, anagrelide is another option, though its use is often limited by toxicities (eg, headaches, dizziness, palpitations, and fluid retention). […] The development of more targeted agents with the potential to meaningfully disrupt the mechanisms driving MPNs provides a lot of optimism for the future in these diseases. […] Hopefully we will be able to raise the bar for response from simply hematologic control and thrombosis prevention toward the more lofty aims of lengthening survival, improving quality of life, and lowering risk of disease progression.

• #2 Essential Thrombocythemia: Definition, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/24031-essential-thrombocythemia

  If you have essential thrombocythemia, you have a high platelet count that isn’t related to another medical condition. […] Healthcare providers may treat essential thrombocythemia with medications that prevent blood clots and/or lower platelet levels. […] Aspirin prevents blood clots. […] Hydroxyurea is a chemotherapy medication that lowers platelet levels. […] Anagrelide lowers platelet levels and helps reduce stroke and heart attack risk. […] Interferon alfa is a form of immunotherapy that keeps abnormal platelets from dividing and multiplying. […] If you have very high platelet levels, your provider may recommend plateletpheresis to lower your platelet levels right away. […] Essential thrombocythemia is an acquired genetic disorder that happens when certain genes mutate. […] Researchers don’t know why these genes mutate, so you can’t prevent that from happening.

• #2 Patients with essential thrombocytosis during pregnancy: Challenges and therapeutic dilemmas

  https://www.oatext.com/patients-with-essential-thrombocytosis-during-pregnancy-challenges-and-therapeutic-dilemmas.php

  Low dose ASA has been frequently used during pregnancy and it is considered safe for the fetus without a significant risk of bleeding for the mother. […] The addition of low-dose ASA showed encouraging results. […] Even if there is no direct evidence of the efficacy of ASA, it seems possible that ASA increases the rate of successful pregnancies. […] JAK2V617F mutation is known to increase thrombosis rate outside pregnancy. Thus, patients caring this mutation possibly are at increased risk for abortions and pregnancy complications during pregnancy and candidates to receive ASA. […] As there are no trials evaluating the role of heparin throughout a high-risk ET pregnancy, the precise benefit is unclear. […] In the absence of other thrombophilic factors or presence of placenta-mediated complications, patients are at increased risk of thromboembolic events during the last few weeks of pregnancy and in the postpartum period.

• #2 Patients with essential thrombocytosis during pregnancy: Challenges and therapeutic dilemmas

  https://www.oatext.com/patients-with-essential-thrombocytosis-during-pregnancy-challenges-and-therapeutic-dilemmas.php

  Treatment recommendations of patients with criteria of cytoreductive treatment (like platelet count 1500000/l or thrombosis) while conceiving, suggest IFNa to be the safest option. […] Treatment with ASA might positively influence the outcome of pregnancy due to reduced probability of placental infarctions. […] The addition of LMWH is not recommended even if there are published reports of successful pregnancies after the combination of both drugs in women with history of severe pregnancy complications including fetal death. […] However, LMWH is reasonable to be considered in women with history of thromboembolic events in the past and high-risk pregnancies for thrombotic potential. […] Thus, prospective studies are needed in order to reconsider the risk of pregnancies, to find the patients who could benefit of more intensive anticoagulation or cytoreductive treatment focusing on the safety of drugs for both the pregnant patient and the fetus.

• #2 Essential Thrombocytosis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/30099

  Hydroxyurea has been shown to reduce both the number of platelets and the number of leukocytes, causing a reduction in thrombosis and myelofibrosis. […] Anagrelide, on the other hand, is a second-line therapy used to reduce platelet count. […] For pregnant ETT patients, concurrent low molecular weight heparin (LMWH) with low-dose aspirin is advocated, the latter withdrawn should bleeding occur. […] The use of Aspirin in the pediatric group raises some trepidation over the appearance of Reyes syndrome. […] Essential thrombocytosis is not curable; however, patients should be aware that to prevent complications from the disease, they have to be compliant with recommended medications. […] It is imperative to find a cure, as complications due to stroke and myocardial infarction could be deadly and cause untimely deaths in high-risk patients.

• #2

  https://journals.lww.com/ijab/fulltext/2015/05030/postoperative_thrombocytosis__an_unusual_case.20.aspx

  The risk of thrombotic complications with reactive thrombocytosis is felt to be low, as 1.6% of patients with reactive thrombocytosis had thrombotic complications in one large case series. […] Even in cases of extreme reactive thrombocytosis, the risk of thrombotic complication is relatively low (4-6%).

• #2

  https://link.springer.com/article/10.1007/s12471-023-01757-4

  An alternative way to prevent recurrent arterial events might be the use of more aggressive, e.g. double antiplatelet, therapy in the first 3-4 years following an arterial thrombotic event. […] Importantly, antiplatelet therapy plus anticoagulants should be used with caution, since their co-use was shown to result in an almost three times higher incidence of major bleeding as compared to either antiplatelet drugs or anticoagulants alone.

• #2 Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist | mijn-bsl

  https://mijn.bsl.nl/essential-thrombocytosis-diagnosis-differential-diagnosis-compli/24011868

  Treatment of ET should be individualised, bearing in mind all possible complications of ET ranging from thrombotic and haemorrhagic events, the presence of risk factors, and the risk of progression to myelofibrosis or myeloid leukaemia. […] With regard to the prevention of thrombotic complications in ET, the advocated approach, based on risk stratification by a history of (arterial or venous) thrombosis, age 60 years, the presence of a JAK2 mutation and cardiovascular risk factors, is presented in Tab. 3. […] An alternative way to prevent recurrent arterial events might be the use of more aggressive, e.g. double antiplatelet, therapy in the first 34 years following an arterial thrombotic event. […] Importantly, antiplatelet therapy plus anticoagulants should be used with caution, since their co-use was shown to result in an almost three times higher incidence of major bleeding as compared to either antiplatelet drugs or anticoagulants alone.

• #2 Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist | springermedizin.de

  https://www.springermedizin.de/essential-thrombocytosis-diagnosis-differential-diagnosis-compli/24010900

  Treatment of ET should be individualised, bearing in mind all possible complications of ET ranging from thrombotic and haemorrhagic events, the presence of risk factors, and the risk of progression to myelofibrosis or myeloid leukaemia. […] With regard to the prevention of thrombotic complications in ET, the advocated approach, based on risk stratification by a history of (arterial or venous) thrombosis, age 60 years, the presence of a JAK2 mutation and cardiovascular risk factors, is presented in Tab. 3. […] An alternative way to prevent recurrent arterial events might be the use of more aggressive, e.g. double antiplatelet, therapy in the first 34 years following an arterial thrombotic event. […] In a large retrospective study of patients with primary thrombocytosis who received either antiplatelet agents, anticoagulation, cytoreductive treatment or underwent phlebotomy after a first thromboembolic complication, only cytoreductive therapy resulted in a significant reduction in recurrent ACS.

• #2 An Update on Current and Emergent Therapies for Essential Thrombocytosis

  https://www.targetedonc.com/view/an-update-on-current-and-emergent-therapies-for-essential-thrombocytosis

  Our understanding of pathophysiology driving Philadelphia chromosomenegative myeloproliferative neoplasms (MPNs) has evolved considerably over the past decade. […] For patients with essential thrombocytosis (ET), the immediate goals remain thrombosis risk reduction and symptom control, but newer therapies on the horizon are likely to change our treatment paradigms considerably for this disease. […] The main goal of current approved therapy is to mitigate the risk of thrombotic events, as the treatments have minimal impact on disease progression. […] For the majority of low-risk patients, low-dose aspirin is recommended, as it aids in preventing clotting, but patients classified as intermediate or high risk are generally advised to undergo cytoreductive therapy. […] The selection of the most suitable cytoreductive agent depends on factors such as the patients comorbidities, tolerability of the treatment, future family planning, and individual preferences.

• #2 Essential Thrombocythemia and Polycythemia Vera Treatments Are Moving Toward Disease Modification

  https://www.onclive.com/view/essential-thrombocythemia-and-polycythemia-vera-treatments-are-moving-toward-disease-modification

  Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia and polycythemia vera. […] A key treatment for ET across risk groups is aspirin (81-100 mg daily), which is used to prevent cardiovascular events. […] In patients with high-risk ET (ie, history of thrombosis, aged 60 years, and presence of JAK2 mutation), the NCCN guidelines recommend concomitant cytoreductive therapies, which may include hydroxyurea (NCCN preferred), peginterferon alpha-2a (PEG; Pegasys), or anagrelide (Agrylin). […] In patients with PV, aspirin (81-100 mg daily) is a core treatment, regardless of whether the patient is considered at low or high risk of cardiovascular events. […] Another key treatment for all patients with PV is phlebotomy, which should strive to maintain a hematocrit level of less than 45%.

• #3 Essential Thrombocythemia: Definition, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/24031-essential-thrombocythemia

  If you have essential thrombocythemia, you have a high platelet count that isn’t related to another medical condition. […] Healthcare providers may treat essential thrombocythemia with medications that prevent blood clots and/or lower platelet levels. […] Aspirin prevents blood clots. […] Hydroxyurea is a chemotherapy medication that lowers platelet levels. […] Anagrelide lowers platelet levels and helps reduce stroke and heart attack risk. […] Interferon alfa is a form of immunotherapy that keeps abnormal platelets from dividing and multiplying. […] If you have very high platelet levels, your provider may recommend plateletpheresis to lower your platelet levels right away. […] Essential thrombocythemia is an acquired genetic disorder that happens when certain genes mutate. […] Researchers don’t know why these genes mutate, so you can’t prevent that from happening.

• #3 https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  Prevention of blood clots (thrombosis) and bleeding (hemorrhaging) is the main objective of treating patients with ET. […] For patients with low-risk disease and no symptoms, the risk of complications may be low the doctor may prescribe low-dose aspirin or no therapy at all. […] On the other hand, for patients with high-risk disease, doctors may prescribe low-dose aspirin and other medications to reduce high platelet counts. […] Low-dose aspirin may reduce the risk of clotting complications. Low-dose aspirin helps prevent platelets from sticking together, making it less likely for blood clots to form that can cause heart attacks or strokes. […] Low-dose aspirin may also increase bleeding risk in patients with extremely high platelet counts. For these reasons, the use of aspirin in treating ET needs to be individualized.

• #3 Essential thrombocythaemia (ET) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/blood-cancer/essential-thrombocythaemia-et

  If you have ET, you have a higher risk of blood clots. Blood clots can sometimes cause a serious condition by blocking blood flow: […] Your haematologist or clinical nurse specialist will give you advice and information about how to reduce your risk. This may include information about the following: […] Your doctor can help you manage any other conditions you have that may also increase your risk of blood clots, such as: […] Your doctors and nurses will give you advice about any lifestyle changes you can make to help reduce your risk. They usually advise you to: […] Most people with ET are treated with aspirin tablets. Aspirin affects the way platelets stick together and helps prevent blood clots. […] If you have a high risk of blood clots, you usually have treatment to reduce the number of platelets in your blood. This is called cytoreductive therapy.

• #3 Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10230439/

  The efficacy of aspirin in controlling vasomotor/microvascular disturbances is well recognized, despite the lack of controlled trials, thanks to the dramatic improvement of patients signs and symptoms in response to aspirin treatment. […] The efficacy of aspirin in primary prevention of major thrombotic events in ET has not been documented by randomized controlled trials. The potential benefit of aspirin is inferred from analogies with its use in polycythemia vera, in which low-dose aspirin has been shown to cause an approximately 60% reduction in the risk of the combined endpoint of non-fatal myocardial infarction, nonfatal stroke or death from cardiovascular causes and of venous thromboembolism, without increasing the risk of bleeding complications. […] Overall, protection from thrombosis by aspirin in ET appeared modest in a systematic review of 24 observational studies including 6,153 ET patients, which showed an estimated 26% reduction of thrombotic events from antiplatelet therapy (aspirin in 80% of patients), lower than that observed in polycythemia vera.

• #3

  https://haematologica.org/article/view/haematol.2022.281388

  The efficacy of aspirin in primary prevention of major thrombotic events in ET has not been documented by randomized controlled trials. […] A recent consensus of experts on the management of CALR-mutated ET recommends a pure observational approach over aspirin prophylaxis in asymptomatic low-risk ET patients without cardiovascular risk factors, while cytoreduction should be preferred over aspirin for low-risk symptomatic patients with a platelet count of 1,000-1,500×109/L. […] Overall, protection from thrombosis by aspirin in ET appeared modest in a systematic review of 24 observational studies including 6,153 ET patients, which showed an estimated 26% reduction of thrombotic events from antiplatelet therapy (aspirin in 80% of patients), lower than that observed in polycythemia vera. […] Low-dose aspirin is the recommended treatment for the control of vascular events in all risk categories of ET patients, with the exception of patients at very low risk, who should be given aspirin for treatment of vasomotor/microvascular disturbances only.

• #3 Essential thrombocythemia treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-017-0041-8

  Current indication for drug therapy in ET and PV is to prevent thrombotic complications, especially in high-risk patients. […] Current treatment in ET is primarily indicated for the purposes of preventing thrombotic complications, which might occur in 10-20% of patients. […] Therefore, it is reasonable to consider further optimization of aspirin therapy in such patients by following twice-daily rather than once-daily schedule, especially in the presence of CV risk factors. […] In this regard, there is evidence for the additional value of aspirin therapy in the prevention of recurrent venous thrombosis. […] Current treatment recommendations in young women wishing to be pregnant or are pregnant include once-daily aspirin for very low-risk or low-risk disease and pegylated IFN- for high-risk disease.

• #3 Primary thrombocythemia Information | Mount Sinai – New York

  https://www.mountsinai.org/health-library/diseases-conditions/primary-thrombocythemia

  If you have life-threatening complications, you may have a treatment called platelet pheresis. It quickly reduces the number of platelets in the blood. […] Long-term, medicines are used to decrease the platelet count to avoid complications. The most common medicines used include hydroxyurea, interferon-alpha, or anagrelide. […] Aspirin at a low dose (81 to 100 mg per day) may decrease clotting episodes.

• #3 Essential thrombocythemia | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/leukemia/what-is-leukemia/myeloproliferative-neoplasms/essential-thrombocythemia

  ET is a chronic disease, which means that it develops slowly over time. […] The goal of treatment for ET is to prevent blood clots. Treatments for ET are given based on your risk of developing bleeding, blood clots and other complications. […] Low-dose Aspirin may be offered for low-risk ET if you have a JAK2 mutation or cardiovascular risk factors (including obesity, smoking tobacco, high blood pressure or high cholesterol) or both. Aspirin may not be appropriate in all situations especially if you have a condition that increases your risk of bleeding. You may also be given Aspirin if you are pregnant to lower the risk of complications from ET. […] Low-dose Aspirin is usually given with drug therapy unless you have a symptom or condition that increases your risk of bleeding. You may also be given Aspirin if you are pregnant to lower the risk of complications from ET.

• #3 Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist | mijn-bsl

  https://mijn.bsl.nl/essential-thrombocytosis-diagnosis-differential-diagnosis-compli/24011868

  Treatment of ET should be individualised, bearing in mind all possible complications of ET ranging from thrombotic and haemorrhagic events, the presence of risk factors, and the risk of progression to myelofibrosis or myeloid leukaemia. […] With regard to the prevention of thrombotic complications in ET, the advocated approach, based on risk stratification by a history of (arterial or venous) thrombosis, age 60 years, the presence of a JAK2 mutation and cardiovascular risk factors, is presented in Tab. 3. […] An alternative way to prevent recurrent arterial events might be the use of more aggressive, e.g. double antiplatelet, therapy in the first 34 years following an arterial thrombotic event. […] Importantly, antiplatelet therapy plus anticoagulants should be used with caution, since their co-use was shown to result in an almost three times higher incidence of major bleeding as compared to either antiplatelet drugs or anticoagulants alone.

• #4 Essential thrombocythemia: Symptoms, treatment, and more

  https://www.medicalnewstoday.com/articles/essential-thrombocythemia

  Currently, there is no way to prevent ET, as it often arises from genetic mutations. However, people can reduce their risk of complications by adopting a heart-healthy lifestyle, including: […] Early detection through routine blood tests is also critical for those with a family history of MPNs or other risk factors.

• #4

  https://haematologica.org/article/view/haematol.2022.281388

  Prevention of recurrent thrombosis in ET patients must follow the general guidelines for secondary prevention in the general population, including antiplatelet agents and anticoagulant drugs, depending on the clinical setting. Primary prevention of thrombosis is based on the prophylactic use of low-dose aspirin (81-100 mg daily) and cytoreduction. Aspirin is recommended for all risk categories, with the exception of patients at very low risk, who should only be given aspirin for treatment of vasomotor/microvascular disturbances; cytoreduction with hydroxyurea or, alternatively, with peginterferon 2a or anagrelide is usually restricted to high-risk patients. […] The efficacy of aspirin in controlling vasomotor/microvascular disturbances is well recognized, despite the lack of controlled trials, thanks to the dramatic improvement of patients signs and symptoms in response to aspirin treatment.

Zobacz więcej